Multi-arm polymeric alkanoate conjugates
Among other aspects, provided herein are multi-armed polymer conjugates comprising an alkanoate-linker, compositions comprising such conjugates, and related methods of making and administering the same. Methods of treatment employing such conjugates and related uses are also provided. The conjugates are prepared with high drug loading efficiencies.
1. A multi-arm polymer conjugate having the following structure,
wherein:
POLY 1 is —(CH 2 CH 2 O) a —;
X is a covalent bond;
R 1 , in each occurrence, is independently selected from the group consisting of H, methyl, ethyl, propyl, n-butyl, isopropyl, isobutyl, a halide, a nitrile, —NO 2 , and —CF 3 ;
n is an integer from 1 to 7;
a ranges from 40 to 500; and
D is a residue of a hydroxyl-containing taxane or a hydroxyl-containing camptothecin having a molecular weight of less than about 800 daltons, where the attachment to D is at a hydroxyl oxygen.
2. The multi-armed polymer conjugate of claim 1 , wherein the weight average molecular weight of POLY 1 ranges from 5,000 to 20,000 daltons.
3. The multi-armed polymer conjugate of claim 1 , wherein the weight average molecular weight of the conjugate is about 20,000 daltons or greater.
4. The multi-armed polymer conjugate of claim 1 , wherein X is —O—.
5. The multi-armed polymer conjugate of claim 1 , wherein D is a residue of paclitaxel or docetaxel.
6. The conjugate of claim 5 , wherein D has the structure:
7. The multi-armed polymer conjugate of claim 5 , having the structure:
where n ranges from about 40 to about 500.
8. The multi-armed polymer conjugate of claim 7 , wherein the overall nominal average molecular weight ranges from about 10,000 to about 80,000 daltons.
9. A pharmaceutical composition comprising a multi-armed polymer conjugate as recited in claim 1 , and a pharmaceutically acceptable carrier.
10. A method of treating cancer in a mammalian subject, said method comprising:
administering a therapeutically effective amount of a conjugate of claim 1 to a subject diagnosed as having one or more cancerous solid tumors over a duration of time effective to produce an inhibition of growth of said solid tumor(s) in said subject, wherein D is an anticancer agent.
11. The method of claim 10 , wherein said cancerous solid tumor type is selected from the group consisting of colorectal, breast, prostate, and non-small cell lung.
12. The composition of claim 9 , wherein said conjugate is characterized by a drug loading of greater than or equal to 92%.